Patient Risk Subgroups Predict Benefit of Adjuvant Chemotherapy in Stage II Rectal Cancer Patients Following Neoadjuvant Chemoradiation and Total Mesorectal Excision

CONCLUSIONS: The survival benefit of AC for clinical stage II RAC following NCRT and TME is most pronounced among intermediate- and high-risk patients as determined by our nomogram. Risk-adaptive AC may be appropriate for selected patients by integrating standard reported pathologic elements into the treatment plan.PMID:33775560 | DOI:10.1016/j.clcc.2021.02.006

Source: Clinical Colorectal Cancer - March 29, 2021 Category: Cancer & Oncology Authors: Samer Naffouje Arvind Sabesan Benjamin D Powers Sophie Dessureault Julian Sanchez Michael Schell Iman Imanirad Ibrahim Sahin Hao Xie Seth Felder Source Type: research